Dr Paul Catchpole, the ABPI’s Director of Value and Access, said: “The ABPI very much welcomes the new initiative announced today by NICE, and the real opportunity it represents for all key stakeholders that play a role in getting new medicines to patients, to engage and interact together more closely.
"Any initiative which strengthens relationships and delivers earlier, more frequent and meaningful dialogue between the life sciences industry, regulators, NICE, and the NHS can only help speed up and improve the adoption and use of innovative medicines for NHS patients.
"The ABPI looks forward to supporting the Office for Market Access and to helping shape and develop its portfolio of offerings and services which will bring real added value to stakeholders, enabling NHS patients across the country to get more timely and consistent access to clinically and cost effective innovative new medicines."
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811